Ensure Performance Continues To Grow, This Is Merck Pharmaceutical Issuer's Strategy To Face The Pandemic Towards Endemic

Merck Indonesia press conference (Photo: Screenshot of Merck Indonesia's virtual channel)

JAKARTA – The German pharmaceutical company PT Merck Tbk. It is said that he has prepared a special strategy in navigating the 2022 business year. One of the focuses of attention is ensuring the company can continue to grow even though the current government has set a transition period from pandemic to endemic.

As is known, one of the industrial sectors that has developed quite a bit in the last two years is the pharmaceutical sector. The reason is that the pandemic conditions have made people's consumption of medicinal and health products soar significantly.

“Indeed, there are some products that are very closely related to the pandemic, but there are also products that have little effect. We have included all of this in the calculation factors when making projections on what the future will look like,” Merck President Director Evie Yulin online after the AGMS on Wednesday, May 25.

According to Evie, the company continues to aim for the target to maintain its achievement as a market leader in the pharmaceuticals segment.

“We must maintain the current market leadership and promote growth above the market. If the current market growth is 4.5 percent, then we have to be above that," he said.

Evie added that the company's internal side is in the form of strengthening the HR base through several strategic efforts.

"The first is the people and culture strategy, which is to ensure that the human resources at Merck Indonesia must always be developed and have a clear plan for what kind of future development will be," he said.

Second, optimizing the company's database as a basis for making important decisions, such as expansion plans or new product launches.

"We want all decisions made based on concrete and complete data, so that this decision is not expected to be too far off from previous estimates," he asserted.

For information, the issuer coded for BRAND stock was recorded as having managed to record revenue growth of 62 percent year on year (yoy) in 2021 to Rp1 trillion from the previous Rp656 billion in 2020. This notch helped support the company's net profit to Rp132 billion last year.

Meanwhile, in the first quarter of 2022, BRAND earned a net profit of Rp. 81 billion or grew 18 percent yoy compared to the same period the previous year of Rp. 69 billion.